Sepsia Therapeutics
Sepsia Therapeutics is dedicated to developing new broad-spectrum biological and cellular therapies against sepsis, a life-threatening condition caused by the host response to infectious agents. Their innovative approach targets host scavenger-like receptors to neutralize inflammation-promoting structures of bacteria and fungi, aiming to provide effective treatments for sepsis, including multidrug-resistant strains. Their products include SIXTIDE, a biological drug, adoptive cell therapies, and medical devices for hemadsorption, with ongoing clinical trials. The company is led by a team of experts and is based in Barcelona, Spain.
Industries
Nr. of Employees
small (1-50)
Sepsia Therapeutics
Plaça Europa 9-11, Torre INBISA. Planta 13. 08908 L'Hospitalet de Llobregat Barcelona Spain
Patents
Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes
US-11660326-B2
View DetailsCombined CD6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
US-11324804-B2
View DetailsProtein product for treatment of infectious diseases and related inflammatory processes
US-8691752-B2
View DetailsCD5 pharmaceutical compositions for the treatment of infectious and inflammatory processes of fungal origin
US-8404633-B2
View Details
Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes
US-11660326-B2
View DetailsCombined CD6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
US-11324804-B2
View DetailsProtein product for treatment of infectious diseases and related inflammatory processes
US-8691752-B2
View DetailsCD5 pharmaceutical compositions for the treatment of infectious and inflammatory processes of fungal origin
US-8404633-B2
View DetailsProducts
Scavenger receptor-derived peptide/protein biologic for sepsis
Injectable short peptides or proteins derived from human scavenger receptors designed to bind microbial PAMPs, inhibit pro-inflammatory signaling and reduce microbial load.
Adoptive CAR lymphocyte therapy for bacterial and fungal infections
Cellular therapy comprising lymphocytes engineered with scavenger-based CARs to target and kill pathogenic bacteria and fungi.
Hemadsorption device for removal of microbial toxins
Medical device for hemadsorption of circulating microbial toxins and inflammatory mediators to prevent systemic inflammation and organ dysfunction in sepsis.
Scavenger receptor-derived peptide/protein biologic for sepsis
Injectable short peptides or proteins derived from human scavenger receptors designed to bind microbial PAMPs, inhibit pro-inflammatory signaling and reduce microbial load.
Adoptive CAR lymphocyte therapy for bacterial and fungal infections
Cellular therapy comprising lymphocytes engineered with scavenger-based CARs to target and kill pathogenic bacteria and fungi.
Hemadsorption device for removal of microbial toxins
Medical device for hemadsorption of circulating microbial toxins and inflammatory mediators to prevent systemic inflammation and organ dysfunction in sepsis.
Services
In vivo evaluation of candidate therapeutics for impacts on survival, microbial load and systemic inflammation in sepsis models.
Production and scale-up of active biological principles for clinical development.
Design and conduct of clinical studies for sepsis therapeutics through Phase III, including evaluation of monotherapy and combination regimens.
In vivo evaluation of candidate therapeutics for impacts on survival, microbial load and systemic inflammation in sepsis models.
Production and scale-up of active biological principles for clinical development.
Design and conduct of clinical studies for sepsis therapeutics through Phase III, including evaluation of monotherapy and combination regimens.
Expertise Areas
- Sepsis therapeutic development
- Host-targeted immunomodulatory therapeutics
- Peptide and protein biologics
- Adoptive cell therapy and CAR engineering
Key Technologies
- Peptide and protein therapeutic design
- Chimeric antigen receptors (CARs)
- Lentiviral vector transduction
- Adoptive lymphocyte therapy